The Use of Tricyclic Antidepressants for Postherpetic Neuralgia - A Case Series

Postherpetic neuralgia (PHN) is one of the most debilitating forms of neuropathic pain that can occur after a herpes zoster infection. PHN can significantly impair patients' quality of life due to persistent neuropathic pain. Current first-line treatments for PHN include anticonvulsants like gabapentin and pregabalin, topical agents such as lidocaine patches, and opioids in severe cases. However, many patients fail to achieve adequate pain control with these medications. Tricyclic antidepressants (TCAs) such as amitriptyline and nortriptyline may be considered as a second-line option, providing relief for patients with refractory pain. TCAs act by modulating neurotransmitters involved in pain pathways, offering analgesia in neuropathic conditions like PHN. This case series reviews four patients with PHN who found significant pain relief with the addition of TCAs after failing multiple other treatments. The patients, aged between 66 and 71, presented with severe PHN and had tried various treatments, including acetaminophen (APAP), nonsteroidal anti-inflammatory drugs (NSAIDs), lidocaine patches, gabapentinoids, and opioids, without achieving adequate pain relief. Each patient was prescribed a TCA, either amitriptyline or nortriptyline, alongside other pain medications. All four patients experienced notable reductions in pain intensity on the Numeric Rating Scale (NRS), resulting in improved daily function and better pain tolerance. Side effects were minimal, with only one patient reporting mild sedation and another reporting transient dry mouth, both of which were manageable. This case series underscores the potential of TCAs in managing PHN, particularly when other medications fail. While the results are promising, further research is needed to confirm the long-term efficacy and safety of TCAs in this patient population.